These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35400368)

  • 1. Rheumatic Complications of Immune Checkpoint Inhibitors.
    Ghosh N; Bass AR
    Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatic Complications of Immune Checkpoint Inhibitors.
    Ghosh N; Bass AR
    Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
    Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
    Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and impact of checkpoint inhibitor-induced irAEs.
    Cappelli LC; Bingham CO
    Nat Rev Rheumatol; 2021 Feb; 17(2):69-70. PubMed ID: 33235330
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
    Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
    Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
    Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
    Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M; Truchetet ME; Schaeverbeke T
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
    Ladouceur A; Ezdoglian A; Sparks JA; Hudson M; Jamal S; Clifford A; Roberts J; Ye C
    Rheum Dis Clin North Am; 2024 May; 50(2):181-199. PubMed ID: 38670720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
    Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2024 Aug; 20(8):873-893. PubMed ID: 38400840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.
    Mullenix C; Ballman M; Chen H; Swift S; McAdams MJ; Tsai YT; Donahue RN; Poretta T; Gupta S; Loehrer PJ; Schlom J; Gulley JL; Rajan A
    Oncologist; 2022 Apr; 27(4):e353-e356. PubMed ID: 35380721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
    Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
    Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging in Rheumatic Immune-related Adverse Events.
    Zhang J; Ni R; Oke I; Calabrese C; Strouse J; Weinmann S; Ladouceur A
    Rheum Dis Clin North Am; 2024 May; 50(2):313-323. PubMed ID: 38670729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
    Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
    Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
    Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.